GMED vs SRTS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

GMED

53.9
AI Score
VS
SRTS Wins

SRTS

57.6
AI Score

Investment Advisor Scores

GMED

54score
Recommendation
HOLD

SRTS

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED SRTS Winner
Revenue 1.55B 22.54M GMED
Net Income 275.87M -4.55M GMED
Net Margin 17.8% -20.2% GMED
Operating Income 332.82M -7.16M GMED
ROE 5.8% -8.9% GMED
ROA 5.0% -7.8% GMED
Total Assets 5.49B 58.30M GMED
Cash 507.75M 24.45M GMED
Current Ratio 4.62 7.38 SRTS
Free Cash Flow 339.32M 2.70M GMED

Relative Price Performance (Last 90 Days)

GMED 1M: -6.3% · 3M: -6.1% SRTS 1M: -8.3% · 3M: -2.3%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $75.60

SRTS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 43.8 · Price: $2.98

Fundamentals Snapshot

Metric GMED SRTS
Market Cap — —
Forward P/E 14.0 -17.2
Trailing P/E 19.2 —
Revenue (TTM) — —
Revenue Growth 0.1% -0.7%
Gross Margin 0.7% 0.4%
Operating Margin 0.2% -1.4%
EPS 3.88 -0.93
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, SRTS is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.